Form 4: Gilead CFO Sells Shares Under Pre-Arranged Trading Plan

Gilead Sciences Chief Financial Officer Andrew D. Dickinson sold 2,500 shares of common stock for $111.03 per share under a Rule 10b5-1 trading plan.

Summary

• Andrew D. Dickinson, Chief Financial Officer of Gilead Sciences, Inc., sold 2,500 shares of the company's common stock.
• The transaction occurred on July 15, 2025, at a price of $111.03 per share.
• Following this sale, Mr. Dickinson directly beneficially owns 162,610 shares of Gilead Sciences common stock.
• The sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted on August 29, 2024.

Sentiment

Score: 5

Explanation: The sale by the CFO is a reduction in insider holdings, which can be seen as slightly negative. However, the execution under a Rule 10b5-1 plan mitigates concerns about it being based on new, non-public information, making the overall sentiment neutral.

Positives

• The transaction was conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled sale not based on new, non-public information.

Negatives

• A reduction in direct beneficial ownership by a key executive, even if pre-planned, could be perceived as a slight negative signal by some investors.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, potentially viewed neutrally due to the pre-planned nature of the sale.

Key Dates

Keywords

Gilead Sciences, GILD, SEC Form 4, Insider Trading, Stock Sale, Andrew D. Dickinson, Chief Financial Officer, Rule 10b5-1 Plan, Equity Transaction